Literature DB >> 21775680

An insertion mutant in DQA1*0501 restores susceptibility to HLA-DM: implications for disease associations.

Tieying Hou1, Henriette Macmillan, Zhenjun Chen, Catherine L Keech, Xi Jin, John Sidney, Michael Strohman, Taejin Yoon, Elizabeth D Mellins.   

Abstract

HLA-DM (DM) catalyzes CLIP release, stabilizes MHC class II molecules, and edits the peptide repertoire presented by class II. Impaired DM function may have profound effects on Ag presentation events in the thymus and periphery that are critical for maintenance of self-tolerance. The associations of the HLA-DQ2 (DQ2) allele with celiac disease and type 1 diabetes mellitus have been appreciated for a long time. The explanation for these associations, however, remains unknown. We previously found that DQ2 is a poor substrate for DM. In this study, to further characterize DQ2-DM interaction, we introduced point mutations into DQ2 on the proposed DQ2-DM interface to restore the sensitivity of DQ2 to DM. The effects of mutations were investigated by measuring the peptide dissociation and exchange rate in vitro, CLIP and DQ2 expression on the cell surface, and the presentation of α-II-gliadin epitope (residues 62-70) to murine, DQ2-restricted T cell hybridomas. We found that the three α-chain mutations (α+53G, α+53R, or αY22F) decreased the intrinsic stability of peptide-class II complex. More interestingly, the α+53G mutant restored DQ2 sensitivity to DM, likely due to improved interaction with DM. Our data also suggest that α-II-gliadin 62-70 is a DM-suppressed epitope. The DQ2 resistance to DM changes the fate of this peptide from a cryptic to an immunodominant epitope. Our findings elucidate the structural basis for reduced DQ2-DM interaction and have implications for mechanisms underlying disease associations of DQ2.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21775680      PMCID: PMC3159820          DOI: 10.4049/jimmunol.1100255

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides.

Authors:  J M Riberdy; J R Newcomb; M J Surman; J A Barbosa; P Cresswell
Journal:  Nature       Date:  1992-12-03       Impact factor: 49.962

2.  Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant.

Authors:  A Sette; S Ceman; R T Kubo; K Sakaguchi; E Appella; D F Hunt; T A Davis; H Michel; J Shabanowitz; R Rudersdorf
Journal:  Science       Date:  1992-12-11       Impact factor: 47.728

Review 3.  The role of the MHC in autoimmunity: an overview.

Authors:  E D Mellins
Journal:  J Rheumatol Suppl       Date:  1992-04

4.  Amino-terminal flanking residues determine the conformation of a peptide-class II MHC complex.

Authors:  Scott B Lovitch; Zheng Pu; Emil R Unanue
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

5.  Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments.

Authors:  P J Peters; J J Neefjes; V Oorschot; H L Ploegh; H J Geuze
Journal:  Nature       Date:  1991-02-21       Impact factor: 49.962

6.  Isolation and characterization of the intracellular MHC class II compartment.

Authors:  A Tulp; D Verwoerd; B Dobberstein; H L Ploegh; J Pieters
Journal:  Nature       Date:  1994-05-12       Impact factor: 49.962

Review 7.  HLA susceptibility genes in celiac disease: genetic mapping and role in pathogenesis.

Authors:  L M Sollid; E Thorsby
Journal:  Gastroenterology       Date:  1993-09       Impact factor: 22.682

8.  Peripheral T cell response to A-gliadin in celiac disease: differential processing and presentation capacities of Epstein-Barr-transformed B cells and fibroblasts.

Authors:  A Franco; E Appella; M F Kagnoff; Y Chowers; K Sakaguchi; H M Grey; A Sette
Journal:  Clin Immunol Immunopathol       Date:  1994-04

9.  Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer.

Authors:  L M Sollid; G Markussen; J Ek; H Gjerde; F Vartdal; E Thorsby
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

10.  Separation of subcellular compartments containing distinct functional forms of MHC class II.

Authors:  Y Qiu; X Xu; A Wandinger-Ness; D P Dalke; S K Pierce
Journal:  J Cell Biol       Date:  1994-05       Impact factor: 10.539

View more
  31 in total

1.  Type 1 diabetes associated HLA-DQ2 and DQ8 molecules are relatively resistant to HLA-DM mediated release of invariant chain-derived CLIP peptides.

Authors:  Zemin Zhou; Eduardo Reyes-Vargas; Hernando Escobar; Brant Rudd; Alan L Rockwood; Julio C Delgado; Xiao He; Peter E Jensen
Journal:  Eur J Immunol       Date:  2016-01-22       Impact factor: 5.532

2.  Cell-surface MHC density profiling reveals instability of autoimmunity-associated HLA.

Authors:  Hiroko Miyadera; Jun Ohashi; Åke Lernmark; Toshio Kitamura; Katsushi Tokunaga
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

3.  Distinct editing functions of natural HLA-DM allotypes impact antigen presentation and CD4+ T cell activation.

Authors:  Miguel Álvaro-Benito; Eliot Morrison; Friederike Ebner; Esam T Abualrous; Marie Urbicht; Marek Wieczorek; Christian Freund
Journal:  Cell Mol Immunol       Date:  2018-11-22       Impact factor: 11.530

4.  HLA-DO Modulates the Diversity of the MHC-II Self-peptidome.

Authors:  Padma P Nanaware; Mollie M Jurewicz; John D Leszyk; Scott A Shaffer; Lawrence J Stern
Journal:  Mol Cell Proteomics       Date:  2018-12-20       Impact factor: 5.911

5.  Epitope Selection for HLA-DQ2 Presentation: Implications for Celiac Disease and Viral Defense.

Authors:  Shu-Chen Hung; Tieying Hou; Wei Jiang; Nan Wang; Shuo-Wang Qiao; I-Ting Chow; Xiaodan Liu; Sjoerd H van der Burg; David M Koelle; William W Kwok; Ludvig M Sollid; Elizabeth D Mellins
Journal:  J Immunol       Date:  2019-03-29       Impact factor: 5.422

6.  Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity.

Authors:  Andrea L Martinez-Skinner; Ram S Veerubhotla; Han Liu; Huangui Xiong; Fang Yu; JoEllyn M McMillan; Howard E Gendelman
Journal:  J Proteome Res       Date:  2013-04-17       Impact factor: 4.466

7.  Susceptibility to HLA-DM protein is determined by a dynamic conformation of major histocompatibility complex class II molecule bound with peptide.

Authors:  Liusong Yin; Peter Trenh; Abigail Guce; Marek Wieczorek; Sascha Lange; Jana Sticht; Wei Jiang; Marissa Bylsma; Elizabeth D Mellins; Christian Freund; Lawrence J Stern
Journal:  J Biol Chem       Date:  2014-07-07       Impact factor: 5.157

8.  A novel method to measure HLA-DM-susceptibility of peptides bound to MHC class II molecules based on peptide binding competition assay and differential IC(50) determination.

Authors:  Liusong Yin; Lawrence J Stern
Journal:  J Immunol Methods       Date:  2014-02-25       Impact factor: 2.303

Review 9.  HLA-DM and HLA-DO, key regulators of MHC-II processing and presentation.

Authors:  Elizabeth D Mellins; Lawrence J Stern
Journal:  Curr Opin Immunol       Date:  2013-12-08       Impact factor: 7.486

Review 10.  Conformational variation in structures of classical and non-classical MHCII proteins and functional implications.

Authors:  Corrie A Painter; Lawrence J Stern
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.